5Kapil R, Nolting A, Roy P, et aL Phannacokinetic properties of combi- nation oxycodone plus rocemic ibuprofen:two randomized, open-label, crossover studies in healthy adult volunteers [J] . Clln her,2004,26 (12) :2015-2025.
6Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management[J]. Minerva Anestesiol,2005,71 (7- 8) :451-460.
4Devulder JE.Subcutaneous morphine superior to intrathecal morphine pain control n a patient with hypernephroma[J].J Clin Am, 1998,10(2):163～165.
5Kim BS, Chung HC.Experience with a controlled-release oral morphine for cancer pain management[J].Postgrad Med J,1991,67(2):86.
6Tsuneto S, Hayashi A, Miyazaki M, et al.A clinical survey of controlled-release morphine sulphate foe cancer pain relief in a Japanese hospice[J].Postgrad Med J, 1991, 67(2):79～81.
7Bloomfield SS, Gussel GB, Mitchell J, et al.Analgesic efficacy and potency of two oral controlled-release morphine preparations[J].Clin Pharmacol Her,1993,53:469.
8Roert F, Robert P.The United States Experience with oral controlled-release morphine[J].Cancer,1989,63:2 348～2 354.
9Maloney CM, Kesner RK, Klein G, et al.The administration of MS contin: clinical implication of use in end stage cancer[J].Am J Hospice Care,1989,6:34.
10Wasylak TY, Abbott FA, Enlish MJ, et al.Reduction of postoperative mobidity following patient controlled analgesia[J].Can J Anesth,1990,37:726.
